These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 34763318

  • 21. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 22. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun 23; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 23. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C.
    Thorac Cancer; 2020 Jan 23; 11(1):176-180. PubMed ID: 31766077
    [Abstract] [Full Text] [Related]

  • 24. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
    Elshatlawy M, Sampson J, Clarke K, Bayliss R.
    Mol Oncol; 2023 Jun 23; 17(6):950-963. PubMed ID: 37149843
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
    Xiang Y, Zhang S, Fang X, Jiang Y, Fang T, Liu J, Lu K.
    Curr Oncol; 2022 Oct 16; 29(10):7816-7831. PubMed ID: 36290895
    [Abstract] [Full Text] [Related]

  • 37. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y.
    Thorac Cancer; 2021 Sep 16; 12(17):2420-2423. PubMed ID: 34324792
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
    Penzel R, Schirmacher P, Warth A.
    J Thorac Oncol; 2012 Jul 16; 7(7):1198-9. PubMed ID: 22706607
    [Abstract] [Full Text] [Related]

  • 40. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S.
    Anticancer Drugs; 2018 Nov 16; 29(10):935-943. PubMed ID: 30074936
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.